Active Ingredient(s):Ado-Trastuzumab Emtansine FDA Approved: * February 22, 2013 Pharm Company: *GENENTECH Category:Cancer
Trastuzumab emtansine, sold under the brand name Kadcyla, is an antibody-drug conjugate consisting of the humanized monoclonal antibody trastuzumab (Herceptin) covalently linked to the cytotoxic agent DM1. Trastuzumab alone stops growth of cancer cells by binding to the HER2 receptor, whereas trastuzumab emtansine undergoes receptor-mediated internalization into cells, is catabol...
* May have multiple approval dates, manufacturers, or labelers. 1 Discussion
Kadcyla 20 mg/ml Intravenous Injection, Powder, Lyophilized, for Solution